Effects of Interleukin-13 and Montelukast on the Expression of Zonula Occludens-1 in Human Podocytes
Yonsei Medical Journal
;
: 426-432, 2015.
Artículo
en Inglés
| WPRIM
| ID: wpr-141635
ABSTRACT
PURPOSE:
The aim of this study was to investigate whether pathologic changes in zonula occludens-1 (ZO-1) are induced by interleukin-13 (IL-13) in the experimental minimal-change nephrotic syndrome (MCNS) model and to determine whether montelukast, a leukotriene receptor antagonist, has an effect on ZO-1 restoration in cultured human podocytes. MATERIALS ANDMETHODS:
Human podocytes cultured on bovine serum albumin-coated plates were treated with different doses of IL-13 and montelukast and then examined for distribution using confocal microscopy and for ZO-1 protein levels using Western blotting.RESULTS:
ZO-1 was internalized and shown to accumulate in the cytoplasm of human podocytes in an IL-13 dose-dependent manner. High doses (50 and 100 ng/mL) of IL-13 decreased the levels of ZO-1 protein at 12 and 24 h (both p<0.01; n=3), which were significantly reversed by a high dose (0.5 microM) montelukast treatment (p<0.01; n=3).CONCLUSION:
Our results suggest that IL-13 alters the expression of ZO-1, and such alterations in the content and distribution of ZO-1 may be relevant in the pathogenesis of proteinuria in the MCNS model.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Proteinuria
/
Quinolinas
/
Western Blotting
/
Microscopía Confocal
/
Interleucina-13
/
Uniones Estrechas
/
Antagonistas de Leucotrieno
/
Relación Dosis-Respuesta a Droga
/
Podocitos
/
Proteína de la Zonula Occludens-1
Límite:
Humanos
Idioma:
Inglés
Revista:
Yonsei Medical Journal
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS